Evidence map›Paper›PMID 41858252›Full record

ArticleCancer medicine2026

Tumor-Infiltrating Immune Cells Are More Abundant in Lung Metastases From Colorectal Cancer Than in Paired Primary Tumors and Their Prognostic Value Depends on Adjuvant Chemotherapy.

Danyil Kuznyecov, Christina Siesing, Halla Vidarsdottir, Jakob Eberhard, Hans Brunnström, Karin Leandersson, Karin Jirström

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Danyil KuznyecovDepartment of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.
Christina SiesingDepartment of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.
Halla VidarsdottirDepartment of Surgery, Landspitali University Hospital, Reykjavik, Iceland.
Jakob EberhardDepartment of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.
Hans BrunnströmDepartment of Clinical Genetics, Pathology and Molecular Diagnostics, Skåne University Hospital, Lund, Sweden.ORCID https://orcid.org/0000-0001-7402-138X
Karin LeanderssonDepartment of Translational Medicine, Cancer Immunology, Lund University, Malmö, Sweden.ORCID https://orcid.org/0000-0001-8254-3137
Karin JirströmDepartment of Clinical Sciences Lund, Division of Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0003-2257-5000

Funding

Cancerfonden 21-1596 PjCancerfonden 24-3644 PjCancerfonden CAN 2018-418Fru Berta Kamprads Stiftelse FBKS 2018-15Skåne Universital Hospital Donations and FundsSwedish governmental funding of clinical research (ALF)
6 · The paper itself

Abstract

introductionThe immune microenvironment plays a crucial role in the progression of colorectal cancer (CRC), but its variation across primary tumors and metastatic sites remains incompletely understood. In this study, we compared the composition and prognostic significance of the immune microenvironment in lung metastases, paired primary tumors, and liver metastases from a retrospective cohort of 216 patients with metastatic CRC who underwent pulmonary metastasectomy in a single Swedish institution.

methodsImmunohistochemistry was applied on tissue microarrays to evaluate CD3

resultsLung metastases exhibited significantly higher infiltration of all immune cell subsets compared to both primary tumors and liver metastases. FoxP3

conclusionThese findings underscore a distinct, more immunologically active immune microenvironment in CRC lung metastases compared to primary tumors and liver metastases, that suggestedly also predicts response to adjuvant chemotherapy. Immune profiling of lung metastases may thus pave the way for improved personalized treatment of these patients.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsLung NeoplasmsLymphocytes, Tumor-InfiltratingAgedBiomarkers, TumorChemotherapy, AdjuvantFemaleForkhead Transcription FactorsHumansImmunohistochemistryMaleMiddle AgedPrognosisRetrospective StudiesTumor MicroenvironmentBiomarkers, TumorForkhead Transcription Factorsadjuvant treatmentB cellscolorectal cancerlung metastasesPD‐L1prognosisT cellstertiary lymphoid‐like structures

Identifiers

PMID41858252
PMCPMC13093549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.